These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 30761820)

  • 1. Mutation-specific therapies and drug repositioning in cystic fibrosis.
    Villella VR; Tosco A; Esposito S; Bona G; Raia V; Maiuri L
    Minerva Pediatr; 2019 Jun; 71(3):287-296. PubMed ID: 30761820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on new and emerging therapies for cystic fibrosis.
    Hudock KM; Clancy JP
    Expert Opin Emerg Drugs; 2017 Dec; 22(4):331-346. PubMed ID: 29264936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of cystic fibrosis treatment.
    Carter SC; McKone EF
    Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards next generation therapies for cystic fibrosis: Folding, function and pharmacology of CFTR.
    Bose SJ; Krainer G; Ng DRS; Schenkel M; Shishido H; Yoon JS; Haggie PM; Schlierf M; Sheppard DN; Skach WR
    J Cyst Fibros; 2020 Mar; 19 Suppl 1(Suppl 1):S25-S32. PubMed ID: 31902693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CFTR: cystic fibrosis and beyond.
    Mall MA; Hartl D
    Eur Respir J; 2014 Oct; 44(4):1042-54. PubMed ID: 24925916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
    McPhail GL; Clancy JP
    Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CFTR: how to treat cystic fibrosis by CFTR-repairing therapies.
    Amaral MD
    Curr Drug Targets; 2011 May; 12(5):683-93. PubMed ID: 21039334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
    Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
    Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The implications of CFTR structural studies for cystic fibrosis drug development.
    Callebaut I; Hoffmann B; Mornon JP
    Curr Opin Pharmacol; 2017 Jun; 34():112-118. PubMed ID: 29096277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
    Bulloch MN; Hanna C; Giovane R
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging medicines to improve the basic defect in cystic fibrosis.
    Fajac I; Sermet-Gaudelus I
    Expert Opin Emerg Drugs; 2022 Sep; 27(3):229-239. PubMed ID: 35731915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies.
    Fanen P; Wohlhuter-Haddad A; Hinzpeter A
    Int J Biochem Cell Biol; 2014 Jul; 52():94-102. PubMed ID: 24631642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Approaches for Potential Therapy of Cystic Fibrosis.
    Sawczak V; Getsy P; Zaidi A; Sun F; Zaman K; Gaston B
    Curr Drug Targets; 2015; 16(9):923-36. PubMed ID: 25557257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes.
    de Poel E; Spelier S; Hagemeijer MC; van Mourik P; Suen SWF; Vonk AM; Brunsveld JE; Ithakisiou GN; Kruisselbrink E; Oppelaar H; Berkers G; de Winter de Groot KM; Heida-Michel S; Jans SR; van Panhuis H; Bakker M; van der Meer R; Roukema J; Dompeling E; Weersink EJM; Koppelman GH; Blaazer AR; Muijlwijk-Koezen JE; van der Ent CK; Beekman JM
    J Cyst Fibros; 2023 May; 22(3):548-559. PubMed ID: 37147251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
    Bell SC; De Boeck K; Amaral MD
    Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.